-
公开(公告)号：US20130263296A1
公开(公告)日：2013-10-03
申请号：US13881777
申请日：2011-10-28
CPC分类号： A61K49/0002 , A61K38/20 , A61K49/0013 , A61K49/0045 , A61K49/04 , A61K51/0491 , A61K51/0495 , C12N15/85 , C12N2710/10043 , C12Q1/6886 , C12Q1/6897 , G01N33/574
摘要： Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.
摘要翻译： 提供了包含与癌症特异性或癌症选择性启动子（例如升高的基因-3（PEG-3）启动子）可操作连接的报告基因的遗传构建体，以及它们用于癌症成像，癌症治疗和组合成像和 治疗方案。 报告基因与癌症特异性或癌症选择性启动子连接并且可进一步基因工程改造，繁殖或选择以具有发展癌症倾向的转基因动物也被提供。
-
2.发明申请公开(公告)号：US20110250129A1
公开(公告)日：2011-10-13
申请号：US13129037
申请日：2009-11-12
申请人： Martin Gilbert Pomper , Yimao Zhang , John Laterra
发明人： Martin Gilbert Pomper , Yimao Zhang , John Laterra
IPC分类号： A61K51/00 , C12Q1/02 , A61K36/752 , A61K31/423 , A61P35/00 , A61K31/409 , A61K31/453 , A61K31/435 , A61K31/5415 , A61P25/00 , C12Q1/66 , A61K31/517
CPC分类号： G01N33/5041 , A61K31/00 , A61K31/423 , A61K31/437 , A61K31/453 , A61K31/472 , A61K31/517 , A61K36/752 , A61K49/0008 , A61K51/02 , A61K51/0453 , A61K51/0455 , A61K51/0459 , C12Q1/66 , G01N33/5008 , G01N2333/705 , G01N2333/70596 , G01N2500/02 , G01N2500/10
摘要： A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described.
摘要翻译： 描述了用于ABCG2抑制剂的基于生物发光成像的高通量测定法。 还描述了ABCG2抑制剂的组成和使用ABCG2抑制剂的方法。
-
公开(公告)号：US20110220418A1
公开(公告)日：2011-09-15
申请号：US13039045
申请日：2011-03-02
申请人： David E. Clark , Lirio Quintero , Anuradee Witthayapanyanon , Alexander John McKellar , Martin Gilbert
发明人： David E. Clark , Lirio Quintero , Anuradee Witthayapanyanon , Alexander John McKellar , Martin Gilbert
CPC分类号： E21B21/068
摘要： Methods and related systems are configured to treat a drilling fluid to cause water droplets to coalesce. One or more phases are thereafter separated from the treated drilling fluid. The oil and/or solids separated from the treated drilling fluid may be added to a base fluid.
摘要翻译： 方法和相关系统被配置为处理钻井液以引起水滴聚结。 此后，从经处理的钻井液中分离出一个或多个相。 从经处理的钻井液中分离的油和/或固体可以加入到基础流体中。
-
4.发明申请LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), BIOLOGICAL EVALUATION, AND USE AS IMAGING AGENTS 有权预防特异性膜抗原（PSMA），生物学评估和成像剂的使用的标签抑制剂公开(公告)号：US20110064657A1
公开(公告)日：2011-03-17
申请号：US12666441
申请日：2008-06-26
IPC分类号： A61K51/08 , C07D401/12 , C07D213/56 , C07F13/00 , C07D257/02 , G01N33/20
CPC分类号： A61K51/0472 , A61K31/145 , A61K31/195 , A61K31/395 , A61K31/4402 , A61K38/06 , A61K51/0402 , C07D213/38 , C07D215/12 , C07D257/00 , C07D257/02 , C07F13/00 , C12Q1/37 , G01N33/57434 , G01N33/60 , G01N2500/04 , A61K2300/00
摘要： The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
摘要翻译： 前列腺特异性膜抗原（PSMA）越来越被认为是癌症成像和治疗的可行靶标。 通过将已知的Tc / Re螯合剂连接到具有或不具有可变长度连接体部分的氨基官能化PSMA抑制剂中来制备各种99mTc / Re标记的化合物。 离体生物分布和体内成像证明了与工程化PSMA + PC3 PIP肿瘤的特异性结合程度。
-
公开(公告)号：US20080149775A1
公开(公告)日：2008-06-26
申请号：US11645029
申请日：2006-12-26
申请人： Storm Dunker , Martin Gilbert
发明人： Storm Dunker , Martin Gilbert
IPC分类号： B64D17/62
CPC分类号： B64D17/62 , B64C39/024 , B64C2201/105 , B64C2201/107 , B64C2201/128 , B64C2201/145 , B64D17/34
摘要： A deployment brake release system for use with an airborne guidance unit (AGU) of a parachute suitable for precision cargo delivery. The parachute includes deployment brake lines secured at one end to the edge of the canopy and connected at the other end through looped ends to motor control lines. The motor control lines are, in turn, engaged with the motor of the AGU. The deployment brake release system includes at least one hook mount having a hook secured to the AGU frame. The looped ends of the deployment brake lines are engaged with the hook during rigging so that, upon deployment, opening forces are applied to the hook mount rather than the motor. After full canopy inflation, the motor, via the motor control lines, pulls on the brake line looped ends to disengage them from the hook, transferring subsequent canopy loads to the AGU motor for the remainder of the flight. A method for releasing the deployment brake lines is also disclosed.
摘要翻译： 与用于精密货物运送的降落伞的空中引导单元（AGU）一起使用的部署制动器释放系统。 降落伞包括一端固定在顶盖边缘的部署制动线，另一端通过环形端连接到电机控制线。 马达控制线又与AGU的马达接合。 部署制动器释放系统包括至少一个钩安装件，其具有固定到AGU框架上的钩子。 在索具期间，展开制动管线的环形端部与钩接合，使得在展开时，打开力被施加到钩安装件而不是马达。 在全冠层膨胀后，电机通过电机控制线拉动制动线环路端部，将其从钩上脱离，将剩余的顶盖负载转移到AGU电机，以用于其余的飞行。 还公开了一种用于释放展开制动线的方法。
-
公开(公告)号：US2653822A
公开(公告)日：1953-09-29
申请号：US10536749
申请日：1949-07-18
申请人： MARTIN GILBERT F
发明人： MARTIN GILBERT F
IPC分类号： B60D1/34
CPC分类号： B60D1/34
-
公开(公告)号：US20120276007A1
公开(公告)日：2012-11-01
申请号：US13537789
申请日：2012-06-29
IPC分类号： A61K51/04 , C07C69/78 , C07C323/57
CPC分类号： A61K51/0402 , A61B6/508 , A61K49/0032 , A61K49/0052 , C07B2200/05 , C07C275/24 , C07C323/59 , C07F11/005 , C12Q1/37 , G01N33/5005 , G01N33/60 , G01N33/62 , G01N33/689 , G01N2333/705
摘要： The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.
摘要翻译： 本发明涉及用一种或多种放射性同位素标记并且适用于表达NAALADase和/或PSMA的组织，器官或肿瘤的成像或治疗性治疗的化合物，特别是不对称的脲化合物。 在另一个实施方案中，本发明涉及使用本发明的放射性标记的化合物，特别是表达本发明的化合物具有亲和力的NAALADase和/或PSMA的组织，器官或肿瘤来成像组织，器官或肿瘤的方法。
-
公开(公告)号：US07408079B2
公开(公告)日：2008-08-05
申请号：US10340864
申请日：2003-01-10
IPC分类号： C07C241/00 , C07C57/30 , C07C229/00
CPC分类号： A61K51/0402 , A61B6/508 , A61K49/0032 , A61K49/0052 , C07B2200/05 , C07C275/24 , C07C323/59 , C07F11/005 , C12Q1/37 , G01N33/5005 , G01N33/60 , G01N33/62 , G01N33/689 , G01N2333/705
摘要： The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.
摘要翻译： 本发明涉及用一种或多种放射性同位素标记并且适用于表达NAALADase和/或PSMA的组织，器官或肿瘤的成像或治疗性治疗的化合物，特别是不对称的脲化合物。 在另一个实施方案中，本发明涉及使用本发明的放射性标记的化合物，特别是表达本发明的化合物具有亲和力的NAALADase和/或PSMA的组织，器官或肿瘤来成像组织，器官或肿瘤的方法。
-
公开(公告)号：US20090117042A1
公开(公告)日：2009-05-07
申请号：US12154445
申请日：2008-05-22
IPC分类号： A61K51/04 , A61K101/02 , A61K101/00 , A61K103/10 , C07C229/00 , C07F13/00 , C07D257/04 , C07C59/00 , C07D209/56
CPC分类号： A61K51/0402 , A61B6/508 , A61K49/0032 , A61K49/0052 , C07B2200/05 , C07C275/24 , C07C323/59 , C07F11/005 , C12Q1/37 , G01N33/5005 , G01N33/60 , G01N33/62 , G01N33/689 , G01N2333/705
摘要： The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.
摘要翻译： 本发明涉及用一种或多种放射性同位素标记并且适用于表达NAALADase和/或PSMA的组织，器官或肿瘤的成像或治疗性治疗的化合物，特别是不对称的脲化合物。 在另一个实施方案中，本发明涉及使用本发明的放射性标记的化合物，特别是表达本发明的化合物具有亲和力的NAALADase和/或PSMA的组织，器官或肿瘤来成像组织，器官或肿瘤的方法。
-
公开(公告)号：US20140227182A1
公开(公告)日：2014-08-14
申请号：US14182690
申请日：2014-02-18
CPC分类号： A61K51/0491 , A01K67/0275 , A01K2217/052 , A01K2217/15 , A01K2217/206 , A01K2227/105 , A01K2267/0331 , A01K2267/0393 , A61K49/0045 , A61K49/0054 , C12N2800/107 , C12N2830/60 , C12N2830/85
摘要： Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter and astrocyte elevated gene 1 (AEG-1) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols, e.g. for imaging and/or treating spontaneous metastasis. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.
摘要翻译： 提供包含与癌症特异性或癌症选择性启动子（例如升高的基因-3（PEG-3）启动子和星形胶质细胞升高的基因1（AEG-1）启动子）可操作地连接的报告基因的遗传构建体，以及其使用方法 在癌症成像，癌症治疗和组合成像和治疗方案中，例如 用于成像和/或治疗自发性转移。 报告基因与癌症特异性或癌症选择性启动子连接并且可进一步基因工程改造，繁殖或选择以具有发展癌症倾向的转基因动物也被提供。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.019 秒)
